• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ASMB

ASMB

Assembly Biosciences, Inc.

NASDAQHealthcareBiotechnologyUS

USD24.57

+0.08 (+0.33%)

Rating:C+

Company Profile

CEO

Jason A. Okazaki

IPO Date

2010-12-17

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$24.57

Prev. Close

$24.49

Day Low

$24.00

Day High

$24.61

52W Low

$15.54

52W High

$39.71

Market Cap

$0.39B

Volume

0.18M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

25.1%

Avg Negative

2.2%

Avg Neutral

72.4%

News Feed

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

GlobeNewsWire·8/18/2021·↑ positive

Assembly Bio Announces Key Promotions to Leadership Team

GlobeNewsWire·8/3/2021·↑ positive

Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors

GlobeNewsWire
·7/20/2021
·↑ positive

Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021

GlobeNewsWire·6/9/2021·↑ positive

Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript

Seeking Alpha·2/28/2021·↓ negative

Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy

Benzinga·2/26/2021·↓ negative

Assembly Biosciences (ASMB) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research·2/25/2021·↑ positive

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection

GlobeNewsWire·2/25/2021·↑ positive

Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know

Zacks Investment Research·2/24/2021·↑ positive